“In the course of starting, managing and advising public and private biotech companies, I have observed what makes drug development companies successful. Companies need a sound strategy, a high quality pipeline, and a management team that has the experience to deliver value to the company’s shareholders and to patients. Naia has touched on each of these aspects: a unique model that allows financing and development flexibility, creating a robust portfolio of late-stage preclinical and clinical assets that will allow it to realize value quickly, inexpensively and at relatively low risk.”
Robert Williamson III
Naia Board of Directors
Robert F Williamson III is the CEO of privately held PharmAkea, a fibrosis and oncology drug development company financed through a partnership with Celgene (NASDAQ: CELG). He has been active in starting and assisting public and private companies through his consultancy, LaSalle Venture Advisers.
Previously, he helped finance and was a Director of Pharmasset, Inc. (NASDAQ: VRUS) which was bought by Gilead (NASDAQ:GILD) for $11B. He was also appointed to the board of Progen Pharmaceuticals (NASDAQ: PGLA) after he sold CellGate to Progen, and has been on numerous private company boards. Earlier, Mr Williamson was Chief Executive Officer of Arriva Pharmaceuticals, President and Chief Operating Officer of Eos Biotechnology – which he sold to Protein Design Labs (NASDAQ: PDLI), and Chief Operating Officer of Pangea / DoubleTwist, Inc – which was acquired in part by Merck (NYSE: MRK) and Hitachi (NYSE: HIT).
Before managing life sciences companies, Mr. Williamson was a partner with The Boston Consulting Group, Inc, and his clients included top pharmaceutical, medical device and health care companies with additional clients in high technology and energy. Mr. Williamson started his career as a research assistant for the Federal Reserve Board of Governors in Washington, DC
He received a BA in Economics from Pomona College and an MBA from Stanford Graduate School of Business.